lasofoxifene has been researched along with nafoxidine in 1 studies
| Studies (lasofoxifene) | Trials (lasofoxifene) | Recent Studies (post-2010) (lasofoxifene) | Studies (nafoxidine) | Trials (nafoxidine) | Recent Studies (post-2010) (nafoxidine) |
|---|---|---|---|---|---|
| 88 | 14 | 24 | 243 | 7 | 3 |
| Protein | Taxonomy | lasofoxifene (IC50) | nafoxidine (IC50) |
|---|---|---|---|
| Estrogen receptor | Rattus norvegicus (Norway rat) | 0.0409 | |
| Estrogen receptor beta | Rattus norvegicus (Norway rat) | 0.0409 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arriola, MW; Brown, TA; Cameron, KO; Cole, MJ; Crawford, DT; Da Silva Jardine, P; Ebbinghaus, CF; Elliott, NC; Gauthier, JW; Ke, HZ; Newhouse, BN; Nickerson, DF; Pan, LC; Pirie, CM; Qi, H; Reinhold, AR; Rosati, RL; Simmons, HA; Sweetnam, PM; Thompson, DD; Tjoa, CM; Tkalcevic, GT; Toler, SM | 1 |
1 other study(ies) available for lasofoxifene and nafoxidine
| Article | Year |
|---|---|
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
Topics: Administration, Oral; Animals; Biological Availability; Bone Density; Breast Neoplasms; Cell Division; Cholesterol; Estrogen Antagonists; Ethinyl Estradiol; Female; Humans; Hypolipidemic Agents; Neoplasms, Hormone-Dependent; Organ Size; Ovariectomy; Pyrrolidines; Rats; Receptors, Estrogen; Tetrahydronaphthalenes; Tumor Cells, Cultured; Uterus | 1998 |